Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion type Assertion NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_head.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion description "[We have also shown that metformin activates the ERK pathway in Ph+ALL cells, SUP-B15, a side effect that can be overcome by U0126 (MEK1/2 inhibitor) or imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_provenance.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion evidence source_evidence_literature NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_provenance.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion SIO_000772 26186064 NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_provenance.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion wasDerivedFrom befree-2016 NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_provenance.
- NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_assertion wasGeneratedBy ECO_0000203 NP1290351.RAidM68zrHn6SlOwdN0-I2SI6jD0kYvCWfvFmiRiSNT7c130_provenance.